Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

By F. Follath, J. Cleland, H. Just, J. Papp, H. Scholz, K. Peuhkurinen, V. Harjola, V. Mitrović, M. Abdalla, E. Sandell and 1 more. The Lancet, 2002

1,125 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. (2007, background): “5 ( 221) 1237 63/620 (10) 75/617 (12) 0.”
[Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]. (2005, background): “Levosimendan has not been associated with an increased frequency of malignant arrhythmias in comparative trials with either placebo,(141,142) or dobutamine.(42) Reductions in the haematocrit, haemoglobin, and plasma potassium, likely secondary to vasodilation and secondary neurohumoral activation, h”
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. (2005, background): “levosimendan) may have beneficial effects on symptoms and end-organ function and are safe.(78)”